Company intelligence / Profile preview

SunBird Enterprises

Cambridge, Massachusetts, United Statessunbirdenterprise.wordpress.com ↗

Ownership: Private
Development stage: Other

Overview

Sunbird Bio has developed proprietary blood-based diagnostic platforms capable of directly detecting and differentiating specific proteins that aggregate in neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Their technology enables earlier and more accurate diagnosis compared to current standards like PET imaging or CSF analysis. The lead program targets Alzheimer's diagnosis via blood draw. No published pivotal trial results yet.

Therapeutic areas: OncologyNeurology
Modalities: Diagnostic test
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on SunBird Enterprises.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SunBird Enterprises.

Explore the full profile